Considering the broad application of micro-dystrophin gene therapy in clinical trials, AAV-based co-delivery of micro-dystrophin and the CRISPR system shows great promise for the efficient treatment of diverse DMD patients. Here, DMD is linked to Duchenne muscular dystrophy.